Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathaniel A Chin

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 5, 2021
Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to knowClaire M Erickson, Nathaniel A Chin, Sterling C Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 11, 2004
NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humansJoseph R Kurian, Sunil U Bajad, Jackie L Miller, et al.
The American Journal of Tropical Medicine and Hygiene|September 19, 2018
Case Report: A Common Source Outbreak of Anisakidosis in the United States and Postexposure Prophylaxis of Family CollateralsAaron F Carlin, Shira Abeles, Nathaniel A Chin, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 31, 2023
Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohortClaire M Erickson, Nathaniel A Chin, Hannah L Rosario, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 16, 2023
The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease researchFred B Ketchum, Nathaniel A Chin, Claire Erickson, et al.
BMC Geriatrics|May 3, 2022
Comparing emergency department use among individuals with varying levels of cognitive impairmentRebecca K Green, Manish N Shah, Lindsay R Clark, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Dementia Care Research and Psychosocial FactorsHayat M Sherif, Lindsay R Clark, Nathaniel A Chin, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 17, 2024
Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudesClaire M Erickson, Fred B Ketchum, Kristin E Basche, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 29, 2022
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and societyClaire M Erickson, Lindsay R Clark, Fred B Ketchum, et al.
The New England Journal of Medicine|March 6, 2024
Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and ScreeningNathaniel A Chin, Debra Dinsmore, Tony Gonzales, et al.
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 5, 2021
Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to knowClaire M Erickson, Nathaniel A Chin, Sterling C Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 11, 2004
NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humansJoseph R Kurian, Sunil U Bajad, Jackie L Miller, et al.
The American Journal of Tropical Medicine and Hygiene|September 19, 2018
Case Report: A Common Source Outbreak of Anisakidosis in the United States and Postexposure Prophylaxis of Family CollateralsAaron F Carlin, Shira Abeles, Nathaniel A Chin, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 31, 2023
Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohortClaire M Erickson, Nathaniel A Chin, Hannah L Rosario, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 16, 2023
The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease researchFred B Ketchum, Nathaniel A Chin, Claire Erickson, et al.
BMC Geriatrics|May 3, 2022
Comparing emergency department use among individuals with varying levels of cognitive impairmentRebecca K Green, Manish N Shah, Lindsay R Clark, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Dementia Care Research and Psychosocial FactorsHayat M Sherif, Lindsay R Clark, Nathaniel A Chin, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 17, 2024
Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudesClaire M Erickson, Fred B Ketchum, Kristin E Basche, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 29, 2022
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and societyClaire M Erickson, Lindsay R Clark, Fred B Ketchum, et al.
The New England Journal of Medicine|March 6, 2024
Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and ScreeningNathaniel A Chin, Debra Dinsmore, Tony Gonzales, et al.
Pageof 9